Celcuity Inc CELC:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/16/24 EDT
17.66quote price arrow up+0.43 (+2.50%)
Volume
198,722
52 week range
8.39 - 22.19
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close17.66
  • 52 Week High22.19
  • 52 Week High Date03/28/24
  • 52 Week Low8.39
  • 52 Week Low Date10/09/23

Key Stats

  • Market Cap537.802M
  • Shares Out30.45M
  • 10 Day Average Volume0.18M
  • Dividend-
  • Dividend Yield-
  • Beta0.87
  • YTD % Change18.26

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close17.66
  • 52 Week High22.19
  • 52 Week High Date03/28/24
  • 52 Week Low8.39
  • 52 Week Low Date10/09/23
  • Market Cap537.802M
  • Shares Out30.45M
  • 10 Day Average Volume0.18M
  • Dividend-
  • Dividend Yield-
  • Beta0.87
  • YTD % Change18.26

RATIOS/PROFITABILITY

  • EPS (TTM)-2.70
  • P/E (TTM)-6.55
  • Fwd P/E (NTM)-6.05
  • EBITDA (TTM)-66.088M
  • ROE (TTM)-46.63%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)26.50%

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Celcuity Inc

 

Profile

MORE
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are...
Brian Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Vicky Hahne CPA
Chief Financial Officer
Address
16305 36th Ave N Ste 100
Minneapolis, MN
55446-4285
United States

Top Peers

SYMBOLLASTCHG%CHG
ALT
Altimmune Inc
8.90+0.03+0.34%
KALV
Kalvista Pharmaceuticals Inc
12.07+0.06+0.50%
OLMA
Olema Pharmaceuticals Inc
9.66-0.19-1.93%
APLT
Applied Therapeutics Inc
4.25-0.15-3.41%
OCS
Oculis Holding AG
11.97-0.04-0.33%